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Production of anti-vimentin antibodies (AVA) after solid organ transplantation are common. Although
classically thought to be expressed mainly within the cytosol, recent evidence demonstrates that extra-
cellular or cell surface expression of vimentin is not unusual. This review examines the evidence to assess
whether AVA contribute to allograft pathology. Clinical studies suggest that AVA are associated with car-
diac allograft vasculopathy in heart transplant recipients. Studies in non-human primates conﬁrm that
production of AVA after renal and heart transplantation are not inhibited by Cyclosporine. Experimental
studies have demonstrated that mice pre-immunised with vimentin undergo accelerated acute rejection
and vascular intimal occlusion of cardiac allografts. Adoptive transfer of hyperimmune sera containing
AVA into B-cell-knock-out mice caused accelerated rejection of allografted hearts, this is clear evidence
that antibodies to vimentin accelerate rejection. AVA act in concert with the alloimmune response and
AVA do not damage syngeneic or native heart allografts. Confocal microscopy of allografted organs in
vimentin immunised mice shows extensive expression of vimentin on endothelial cells, apoptotic leuko-
cytes and platelet/leukocyte conjugates, co-localising with C4d. One explanation for the ability of AVA to
accelerate rejection would be ﬁxation of complement within the graft and subsequent pro-inﬂammatory
effects; there may also be interactions with platelets within the vasculature.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Autoantibodies to vimentin (AVA) are commonly produced by
patients with autoimmune diseases such as Lupus and rheumatoid
arthritis [1,2], they are also found after solid organ transplantation
[3–5]. Vimentin is an intermediate ﬁlament protein found in cells
of mesenchymal origin, hence it is expressed within the cytosol
of adult leukocytes, ﬁbroblasts and endothelial cells. However, it
can be expressed on the surface of cells and be secreted under cer-
tain conditions making it of interest as an antigen which can elicit
an immune response. The evidence suggests that production of
autoantibodies to vimentin reﬂect tissue damage, but whether
anti-vimentin antibodies accelerate or accentuate tissue damage
is less certain. The purpose of this review is to describe the distri-
bution of vimentin within tissues and organs and assess the evi-
dence from clinical and experimental studies that autoantibodies
to vimentin contribute to allograft pathology.2. Distribution and isoforms of vimentin
The most abundant common form of vimentin, detected on
reducing gels is a 55-kDa molecule, representing intermediate ﬁl-
aments. Vimentin is composed of three domains; the amino-termi-
nal domain (head domain), the central core (rod domain) and the
carboxy-terminal domain (tail domain). Vimentin is expressed on
the cell surface of apoptotic T cells [6] and neutrophils [7]. Using
monoclonal antibodies to the different domains of vimentin, it
has been determined that the tail domain (reacting with the V9
antibody) is exposed on apoptotic neutrophils [7], while both rod
and tails are expressed on the surface of apoptotic T cells [6]. The
molecule has several cleavage sites for caspase 3 and caspase 8
and caspase-dependent cleavage of vimentin is an essential pre-
requisite for apoptosis [8]. During apoptosis nuclear and cytosolic
antigens become disorganised, resulting in exposure of cryptic epi-
topes [9], raising the possibility that apoptotic cells act as reser-
voirs of autoantigens [10]. In view of the fact that apoptosis
accompanies many stages of allograft rejection, there is the possi-
bility that apoptotic cells stimulate production of autoantibody to
vimentin. In addition, vimentin is expressed on the cell surface of
activated platelets and is secreted by activated macrophages
[11,12]. Further evidence of cell surface expression and secretion
of vimentin was provided by Xu et al [13]. Xu et al demonstrated
that the monoclonal antibody Pal-E, used for many years as a mar-
ker of endothelial cells, recognises a high molecular weight form of
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nal surface of Human Microvascular Endotheial Cells (HMEC).
Pal-E did not stain the intermediate ﬁlaments of the HMEC. The
authors performed further experiments which suggest the extra-
cellular and secreted form of vimentin is formed as a result of
post-translational protein modiﬁcation. These authors also demon-
strated that cultured HMEC secrete Pal-E reactive vimentin, of both
55 kDa and 120 kDa, and that Pal-E reactive vimentin is found in
human plasma. The biological function of cell-surface and secreted
vimentin found in blood is not known, but evidence suggests that
vimentin may regulate movement of circulating lymphocytes [13–
15]. However, others have demonstrated that Pal-E reacts not with
vimentin but with plasmalemmal vesicle 1 (PV-1) also called fen-
estrated endothelial-linked structure protein (FELS) [16] and Jaa-
louk et al have determined that this antibody reacts with an
epitope of human neuropilin-1 (NRP-1) found in endothelial cells
[17]. Bilalic et al have reported that patients on dialysis make
AVA to the 49 and 60 kDa isoforms and that activated human T
cells express the 49 kDa isoform [18]. These authors suggest that
different isoforms may be expressed by activated or damaged cells
within organ allografts. Post-translational modiﬁcation of vimentin
caused by oxidative stress or citrullination will result in a molecule
with a different structure to the native molecule, and hence likely
to be recognised by the immune system not as an auto-antigen but
as heterologous protein. Hence assaying antibodies to citrullinated
-vimentin is a more sensitive assay for measuring disease severity
of rheumatoid arthritis than assaying antibodies to native vimentin
[19]. The studies descried above demonstrate the heterogeneity
of vimentin within different tissues, likely caused by post-
translational modiﬁcation. These studies also suggests that AVA
produced by different patients recognise different antigenic epitopes
of vimentin, determined by the cellular source of the vimentin.
A number of studies have investigated expression of vimentin
on organs before and after transplantation. Immunocytochemistry
of human and non-human primate hearts has demonstrated that
vimentin is expressed within endothelial cells and it is strongly ex-
pressed on the luminal surface of blood vessels showing graft vas-
culopathy [3], isoforms were not investigated. This reﬂects
endothelial expression of cell-surface vimentin and also probably
reﬂects its presence in proliferating/migrating smooth muscle
cells. Vimentin is not expressed by adult cardiomyocytes. In kid-
neys, normal tubular cells are negative for vimentin, but during
rejection the cytosol of some tubular epithelial cells become
vimentin positive [4]. Similarly, the cytosol of reactive, regenera-
tive or apoptotic renal tubular cells are vimentin positive [20]. Re-
nal interstitial cells constitutively express vimentin, and
expression increases during rejection [4] and ischaemic injury
[21]. Further investigations of the isoforms and the precise cellular
localisation of vimentin before and after rejection would be
informative.3. Clinical studies
It was initially shown in 2001 that heart transplant patients
produce IgM anti-vimentin antibodies within 2 years of transplan-
tation and that higher titres in the ﬁrst two years were predictive
of cardiac allograft vasculopathy (CAV) at 5 years [5]. In this study
IgM antibody was detected but not IgG antibodies and none of the
patients had AVA prior to transplantation. Nath et al have also re-
ported signiﬁcantly higher levels of antibodies to vimentin in pa-
tients who develop CAV [22], but whether these were IgM or IgG
antibodies was not reported. These authiors did not investigate
pre-transplant levels of AVA. An increased frequency of CD4+ T
cells that secrete IL-17 in response to vimentin was also found in
patients with CAV along with a decrease in IL-10 secreting cells,indicating breakdown of tolerance to vimentin in patients with
CAV [22]. Barber et al using A⁄02:01 vimentin binding tetramers,
detected self-restricted CD8+ T cells which bound to vimentin tet-
ramers in eight cardiac transplant recipients [23]. Together these
results demonstrate breakdown of tolerance to vimentin and
development of autoreactive vimentin speciﬁc CD4+ and CD8+ T
cells in cardiac transplant recipients.
Studies in clinical renal transplantation have demonstrated that
patients make AVA after renal transplantation [24]. Carter et al
demonstrated that recipients of kidneys from non-heart-beating
donors (with long ischaemic times) produced signiﬁcantly higher
levls of AVA at 1 month and 6 months than recipients of kidneys
from heart beating donors (with shorter ischaemic times). A recent
study of renal transplantation has suggested that some patients
have IgG AVA prior to transplantation and these patients are more
likely to develop chronic graft vasculopathy (Besarani D, Cerundolo
L, Smith JD, Procter J, Barnado MCN, Roberts ISD, Friend PJ, Rose
ML, Fuggle SV, in preparation). Studies of the factors which inﬂu-
ence production of AVA prior to renal transplantation would be
of interest. Bilalic et al performed a proteomic study of sera from
28 patients on dialysis awaiting renal transplantation [25] and dis-
covered many made autoantibody. Autoantibodies to the 60 kDa
and 49 kDa isoform of vimentin were amongst the most common,
suggesting that prolonged dialysis’ may be a risk factor for AVA.
Our own extended studies of patients awaiting thoracic organ
transplantation (350 heart and 458 lungs, during the period
1998–2012) detected only 10 and 6%, respectively of patients with
pre-transplant IgM AVA, IgG were not sought (Rose ML, Smith JD
unpublished data). However, it maybe that patients undergoing
re-transplantation have AVA, as may patients with pre-exisiting
autoimmune diseases.
Nath et al have reported that production of AVA in cardiac
transplant recipients is associated with AMR in the ﬁrst year after
transplantation [22], and that these antibodies preceded diagnosis
of AVA by several months. Our own studies of AMR in heart trans-
plant patients investigated 17 patients with late AMR (Smith JD
and Rose ML, unpublished); in 15 cases donor speciﬁc HLA anti-
bodies were found at the time of diagnosis of AMR and in two pa-
tients IgG AVA were found at the same time. Whereas it is not
surprising to ﬁnd AVA concomitantly with donor speciﬁc antibod-
ies to HLA, it is of more interest that In two patients, IgG AVA were
detected at the time of diagnosis of AMR, in the absence of donor
speciﬁc HLA antibodies. The possibility that other autoantibodies
(which were not investigated) contributed to AMR cannot be
excluded.4. Effects of immunosuppressive drugs
Studies in non-human primates conﬁrm production of AVA is
associated with solid organ transplantation and is not sensitive
to Cyclosporine. Azimzadeh et al studied heart-transplanted cyno-
molgus monkeys and demonstrated that IgM/IgG AVA were elabo-
rated within 30 days in unmodiﬁed acute rejection and similarly
produced in animals treated with Cyclosporine [3]. CD154 block-
ade did not prevent production of IgM AVA but did delay the
appearance of IgG AVA. It is interesting to note that elution of anti-
bodies from hearts of monkeys with CAV were shown to contain
AVA as measured by ELISA, but hearts from normal monkeys did
not contain AVA. Imunocytochemical examination of transplanted
hearts from cyomolgus monkeys with positive IgM AVA titres
showed presence of C4d in cardiac biopsies, in the absence of
detectable alloantibodies, suggesting that IgM AVA ﬁx comple-
ment. Jonker at al studied AVA in rhesus monkeys following renal
transplantation [4] and also demonstrated production of AVA was
very common, occurring in 31/37 animals and was not inhibited by
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ade. In both studies elaboration of AVA was associated with graft
vasculopathy, although some animals developed graft vasculopa-
thy in the absence of detectable AVA. Hence AVA are a contributing
factor in the pathogenesis of chronic rejection, either indirectly as a
marker of tissue damage or directly (mechanisms described be-
low). Studies in heart transplant recipients have also demonstrated
different sensitivities to immunosuppressive drugs, hence produc-
tion of IgM AVA was signiﬁcantly less in patients receiving myoco-
phenolate mofetil (MMF) than those receiving azathioprine [26].
Production of HLA antibodies were also reduced by MMF.5. Insights into mechanisms from experimental studies
Immunisation of mice with two injections of recombinant
mouse vimentin, one of them in the presence of Complete Freund’s
Adjuvant (CFA) breaks tolerance to vimentin [27]. Such mice pro-
duce high titres of IgG and IgM AVA for 2–12 weeks, the predom-
inant subclass of IgG being the complement ﬁxing IgG2b
isoptype. T cells from the spleens of vimentin immunised mice
produced IFNg when re-stimulated with vimentin in vitro – dem-
onstrating a strong Th1 response to mouse vimentin. When these
mice were transplanted with hearts differing at multiple minor
histocompatibilty antigens (129/sv donors into C57BL/6 recipients,
transplanted 7 days after the booster injection of vimentin) there
was accelerated rejection in vimentin immunised mice compared
to mice immunised with control protein hen-egg lysozyme (8.4+/
 1.5 days compared to 13.3+/ 2.2 days, p = <0.0001). Transplan-
tation of syngeneic hearts or isografts (from C57BL/6 donors) into
vimentin immunised C57BL/6 recipients did not result in rejection.
The minor histocompatibility combination was chosen because
C57BL/6 mice do not make alloantibodies to 129/sv donors [27],
hence presence of C4d in the hearts can be attributed to AVA.
C4d was found in the hearts of vimentin immunised mice rejecting
129/sv hearts, as was presence of P-selectin on endothelial cells.
Signiﬁcantly more CD41 platelets and T cells were found in grafts
of vimentin -immunised mice and AVA were eluted from rejected
hearts. Adoptive transfer of hyperimmunised sera from vimentin-
immunised rabbits into B-cell knock-out mice bearing 129/sv
hearts resulted in accelerated rejection, demonstrating a clear role
for AVA in rejection of cardiac allografts [27]. It is important to
note that AVA alone are not sufﬁcient to cause graft damage, iso-
grafts continued to beat for 90 days in the presence of high titre
of IgG AVA brought about by repeated immunisation of recipients
with vimentin following transplantation; isografts at the end of
this period did not show any signs of myocyte damage or graft vas-
culopathy. In this respect, the anti-vimentin response is unlike the
autoimmune response to cardiac myosin [28,29] or collagen [30]
which causes damage to isografts. Confocal microscopy of rejecting
allografts in vimentin immunised mice showed much higher levels
of exposed vimentin than isografts [27]. In isografted hearts,
vimentin expression was low at day 2 and was conﬁned to some
leukocytes and endothelial cells, in allografts there was extensive
expression of vimentin on apoptosing leukocytes and platelet-leu-
kocyte conjugates co-localising with C3d deposition. There was
also expression of vimentin on non-apoptotic endothelial cells
co-localising with C3d deposition. It seems likely therefore that
damage by AVA is caused by retention of complement ﬁxing AVA
within allografts, to apoptotic cells, activated platelets and endo-
thelial cells. Deposition of C4d and C3d are highly inﬂammatory
and will accentuate the inﬂammatory response [31]. There have
been no clinical studies investigating whether the isotype of IgG
antibodies made to vimentin are the complement ﬁxing isotypes
(IgG3 and IgG1 in humans). However after cardiac transplantation
the large majority of AVA are IgM, which ﬁx complement.6. Interaction with platelets and graft vasculopathy
In vitro studies have demonstrated that normal blood treated
with patient sera containing high AVA IgM titres or with a vimen-
tin speciﬁc monoclonal IgM leads to activation of platelets demon-
strated by induced expression of P-selectin, ﬁbrinogen, tissue
factor and formation of platelet-leukocyte conjugates [32]. Normal
blood would not be expected to contain activated platelets and in
these studies it was demonstrated that AVA did not bind to plate-
lets in the blood but to the 10% of leukocytes in normal blood that
express vimentin on their cell surface, causing release of Platelet
Activating Factor (PAF) which then activated platelets. Activated
platelets express vimentin [12], hence allowing further interaction
between AVA and platelets. The interaction of AVA with neutro-
phils and platelets, produces a pro-thrombotic phenotype which
may contribute to the pathogenesis of thrombotic events that oc-
cur in autoimmune diseases as well as the thrombotic events that
are associated with allograft vasculopathy. Similarly it has been ar-
gued that HLA antibodies to MHC class I antigens (constitutively
present on platelets) act to potentiate graft rejection via activation
of platelets [33]. Two experimental models of cardiac allograft vas-
culopathy were used to demonstrate that pre-immunisation of
recipients with vimentin in CFA results in accelerated occlusion
of blood vessels with smooth muscle cells [34]. Transplantation
of 129/sv hearts into non-immunosuppressed C57BL/6 represents
a multiple minor mismatch and results in acute rejection in 12–
14 days [27]. In order to attenuate acute rejection and allow
cardiac allograft vasculopathy (CAV) to develop, it is necessary to
partially deplete circulating T cells with monoclonal antibodies,
this results in CAV detected at about 3 weeks after transplantation
[34]. Two models of CAV were used, transplantation of 129/sv into
T cell depleted C57BL/6 and transplantation of FVB hearts into non-
immunosupressed DBA/1, in both cases this results in signiﬁcant
intimal occlusion of donor coronary blood vessels (CAV) at days
30 and days 18, respectively [34]. When mice had been immunised
with mouse vimentin to achieve high IgM and IgG titres and trans-
planted when titres were high, intimal occlusion was signiﬁcantly
greater at the times studied [34]. Confocal microscopy of grafts
with luminal occlusion demonstrated co-localisation of vimentin
on the luminal surface of endothelial cells with C3d, and co-local-
isation of vimentin with CD45 leukocytes in the graft. Vimentin
also co-localised with CD41 platelets which were expressing
CD62P. Immunisation of recipients with vimentin also caused in-
creased inﬂux of T cells in the hearts of these recipients. It is unli-
kely that autoreactive T cells damage the hearts because
autoreactive T cells are MHC restricted and hence will not recog-
nise vimentin on graft cells; however, antibodies are not MHC re-
stricted and can presumably recognise peptides on any surface.
Similar to the explanation of pathogenic effects of AVA on acute
rejection, it is proposed that AVA become retained within the allo-
graft during chronic rejection due to endothelial cells and apopto-
sing leukocytes expressing extracellular vimentin. A pro-coagulant
microvasculature is associated with graft vasculopathy in humans.
Hence the presence of ﬁbrin deposition [35] and depletion of tissue
plasminigen activator in the microvessels are predictive of heart
transplant patients who develop CAV [36].7. Summary
Although classically considered to be only expressed in the
cytosol as intermediate ﬁlaments, it is now clear that isoforms of
vimentin are also expressed on the cell surface and secreted under
certain conditions. Vimentin is abundantly expressed in tissue as a
result of tissues damage, as demonstrated by clinical and experi-
mental studies. Elaboration of AVA probably reﬂects breaking of
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within an inﬂammatory milieu; although it is also possible that
antibodies are made to post-translationally modiﬁed proteins,
which may not require breaking of tolerance. Experimental studies
have shown that production of high titre IgG to vimentin on its
own does not cause damage to the syngeneic hearts [27] or native
hearts (Mahesh and Rose unpublished) – hence prior damage to
the transplanted organ is necessary for AVA to accelerate rejection.
Prior damage is likely to be due to the alloimmune response. The
simplest explanation for the damaging effects of AVA is that AVA
ﬁx complement within the allograft and the presence of comple-
ment has a pro-inﬂammatory effect. There is also the possibility
of AVA interaction with neutrophils and platelets which may lead
to platelet activation and a thrombotic milieu within the vascula-
ture of the allograft. Until now, the majority of investigators
have used ELISA to whole vimentin molecules to detect AVA, more
precise associations with pathogenesis may be found using more
speciﬁc assays to vimentin isoforms or to modiﬁed vimentin.
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